Qihong Zhao

Summary

Affiliation: Bristol-Myers Squibb
Country: USA

Publications

  1. ncbi Receptor density dictates the behavior of a subset of steroid ligands in glucocorticoid receptor-mediated transrepression
    Qihong Zhao
    Department of Immunology, Bristol Myers Squibb, Route 206 and Province Line Road, Princeton, NJ 08540, USA
    Int Immunopharmacol 3:1803-17. 2003
  2. ncbi Inflammation, autoimmunity, and atherosclerosis
    Qihong Zhao
    Research and Development, Bristol Myers Squibb Company, Route 206 and Province Line Road, Princeton, NJ 08543, USA
    Discov Med 8:7-12. 2009
  3. ncbi Dual targeting of CCR2 and CCR5: therapeutic potential for immunologic and cardiovascular diseases
    Qihong Zhao
    Research and Development, Bristol Myers Squibb, Princeton, New Jersey 08543, USA
    J Leukoc Biol 88:41-55. 2010
  4. ncbi Discovery of a small molecule antagonist of the parathyroid hormone receptor by using an N-terminal parathyroid hormone peptide probe
    Percy H Carter
    Pharmaceutical Research Institute, Bristol Myers Squibb Company, Princeton, NJ 08543 4000, USA
    Proc Natl Acad Sci U S A 104:6846-51. 2007
  5. ncbi gamma-Lactams as glycinamide replacements in cyclohexane-based CC chemokine receptor 2 (CCR2) antagonists
    Robert J Cherney
    Research and Development, Bristol Myers Squibb Company, Princeton, NJ 08543 4000, USA
    Bioorg Med Chem Lett 20:2425-30. 2010
  6. ncbi Clinically validated approaches to the treatment of autoimmune diseases
    Percy H Carter
    Bristol Myers Squibb Company, Research and Development, Rt 206 and Province Line Road, Princeton, NJ 08543, USA
    Expert Opin Investig Drugs 19:195-213. 2010

Detail Information

Publications6

  1. ncbi Receptor density dictates the behavior of a subset of steroid ligands in glucocorticoid receptor-mediated transrepression
    Qihong Zhao
    Department of Immunology, Bristol Myers Squibb, Route 206 and Province Line Road, Princeton, NJ 08540, USA
    Int Immunopharmacol 3:1803-17. 2003
    ..These results have clearly demonstrated, for the first time, an effect of receptor density on the agonist and antagonist properties of RU486 and MPA in GR-mediated transrepression...
  2. ncbi Inflammation, autoimmunity, and atherosclerosis
    Qihong Zhao
    Research and Development, Bristol Myers Squibb Company, Route 206 and Province Line Road, Princeton, NJ 08543, USA
    Discov Med 8:7-12. 2009
    ....
  3. ncbi Dual targeting of CCR2 and CCR5: therapeutic potential for immunologic and cardiovascular diseases
    Qihong Zhao
    Research and Development, Bristol Myers Squibb, Princeton, New Jersey 08543, USA
    J Leukoc Biol 88:41-55. 2010
    ..It also examines potential safety issues associated with such dual targeting...
  4. ncbi Discovery of a small molecule antagonist of the parathyroid hormone receptor by using an N-terminal parathyroid hormone peptide probe
    Percy H Carter
    Pharmaceutical Research Institute, Bristol Myers Squibb Company, Princeton, NJ 08543 4000, USA
    Proc Natl Acad Sci U S A 104:6846-51. 2007
    ..These studies led to the identification of the benzoxazepinone SW106, a previously unrecognized small molecule antagonist for the PPR. The binding of SW106 to the PPR was rationalized by using a homology receptor model...
  5. ncbi gamma-Lactams as glycinamide replacements in cyclohexane-based CC chemokine receptor 2 (CCR2) antagonists
    Robert J Cherney
    Research and Development, Bristol Myers Squibb Company, Princeton, NJ 08543 4000, USA
    Bioorg Med Chem Lett 20:2425-30. 2010
    ..0 nM and chemotaxis IC(50) = 0.5 nM) and improved metabolic stability over its parent glycinamide...
  6. ncbi Clinically validated approaches to the treatment of autoimmune diseases
    Percy H Carter
    Bristol Myers Squibb Company, Research and Development, Rt 206 and Province Line Road, Princeton, NJ 08543, USA
    Expert Opin Investig Drugs 19:195-213. 2010
    ..Although many of these diseases are rare, the collective prevalence of autoimmune diseases in the United States alone is between 5 and 8%, and is increasing...